ENVB - CIK 0000890821
The table below shows Enveric Biosciences, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | - | - | - | - | - | - |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets | $4.94M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.73M |
| $3.58M |
| $18.43M |
| $17.74M |
| $2.28M |
| Property, plant & equipment | $159.23K | $305.78K | $507.38K | $677.49K | $294.43K | - |
| Goodwill | - | - | $1.59M | $1.59M | $1.59M | - |
| Total assets | $5.10M | $3.08M | $4.30M | $19.55M | $26.72M | $4.10M |
| Accounts payable | $581.02K | $521.75K | $1.22M | $463.27K | - | - |
| Total current liabilities | $918.40K | $1.49M | $2.34M | $4.00M | $2.08M | - |
| Long-term debt | - | - | - | - | - | $740.34K |
| Total liabilities | - | - | - | $4.00M | $4.41M | $681.25K |
| Retained earnings | -$114.85M | -$106.07M | -$96.50M | -$79.21M | -$60.74M | -$11.76M |
| Total equity | $4.18M | $1.59M | $1.96M | $14.67M | $22.31M | $3.42M |